Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2100-2108

  Parton, Marina ^a   Krajewski, Stanislaw ^b   Smith, Ian ^a   Krajewska, Maryla ^b   Archer, Caroline ^a   Naito, Mihikito ^c   Ahern, Roger ^a   Reed, John ^b   Dowsett, Mitchell ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; CARBOPLATIN; CASPASE 3; CASPASE 6; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA FRAGMENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN; MITOXANTRONE; MONOCLONAL ANTIBODY KI 67; POLYCLONAL ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; TAMOXIFEN; UNCLASSIFIED DRUG; AC PROTOCOL; ANTINEOPLASTIC AGENT; BIRC4 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP6 PROTEIN, HUMAN; CASPASE; DEOXYRIBONUCLEASE; DFFB PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FPEPIR REGIMEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN; TUMOR MARKER; TUMOR PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ANTIBODY DETECTION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME ACTIVATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; NICK END LABELING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE FIXATION; AGED; BREAST TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, INFILTRATING DUCT; CARCINOMA, LOBULAR; CASPASES; CISPLATIN; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASES; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMAN; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGE; NEOPLASM PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL; CARCINOMA, DUCTAL, BREAST; CASPASE 3; CASPASE 6; HUMANS; MIDDLE AGED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0035992283     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
4. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
5. A prognostic index in primary breast cancer
6. Efficacy and Safety of Herceptin as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
7. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
8. Primary systemic therapy in operable breast cancer
9. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer
10. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute
11. A human tumour model
12. Apoptosis induced by anticancer drugs
13. Apoptosis in breast cancer as related to histopathological characteristics and prognosis
14. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival
15. Apoptosis during breast carcinoma progression
16. Preoperative chemotherapy induces apoptosis in early breast cancer
17. Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital Experience
18. Apoptosis and proliferation as predictors of chemotherapy response in breast cancer patients
19. Histological grading and prognosis in breast cancer
20. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
21. Prognostic importance of c-erbB-2 expression in breast cancer
22. Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer
23. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
24. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease
25. ASKI mediates apoptotic cell death induced by genotoxic stress
26. A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas
27. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy
28. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity
29. Expression of Bcl-2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis
30. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis
31. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions
32. Induction of apoptosis and reduction in proliferation 24 hours after chemotherapy in early breast cancer
33. bcl-2 and apoptosis in lymph node positive breast carcinoma
34. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers
35. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion
36. Immunohistochemistry of Caspase3/CPP32 in human stomach and its correlation with cell proliferation and apoptosis
37. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma
38. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2. MiB1, pS2 and GST pi
39. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
40. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy
41. ERBB2 oncogene in human breast cancer and its clinical significance
42. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
43. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
44. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
45. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers
46. Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2
47. Balancing cell life and death: Bax, apoptosis, and breast cancer
48. Mitochondrial control of apoptosis
49. Wang a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
50. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis
51. Williams a human nuclease regulated by the caspase-sensitive inhibitor DFF45
52. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
53. X-linked IAP is a direct inhibitor of cell-death proteases
54. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases
55. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias
56. Emerging roles of caspase-3 in apoptosis